The evidence base for diagnosis and management of ALS is still weak, and curative therapy
is lacking. Nonetheless, early diagnosis and symptomatic therapy can profoundly influence …

Introduction Amyotrophic lateral sclerosis (ALS) is a disease with very poor prognosis, and a
mortality of 50% at 18 months after diagnosis. Multidisciplinary units attempt to improve the …

Despite being one of the most devastating diseases known, there is little evidence for
diagnosing and managing patients with amyotrophic lateral sclerosis (ALS). Although …

ALS is a progressive neurodegenerative disease that causes degeneration of the motor
neurons which leads to paralysis and respiratory failure. Despite the lack of a cure …

Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal disease with unique demands on
patients and carers. Patients and methods: The total burden of care and burden components …

Background: The evidence base for the diagnosis and management of amyotrophic lateral
sclerosis (ALS) is weak. Objectives: To provide evidence‐based or expert recommendations …

Abstract Objective: The Ljubljana ALS Centre, established in 2002, is the only tertiary center
for amyotrophic lateral sclerosis (ALS) in Slovenia. The aim of our study was to evaluate the …

Amyotrophic lateral sclerosis (ALS), first described by Jean-Martin Charcot in the 1870s, is
an age-related disorder that leads to degeneration of motor neurons. The disease begins …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative
disorder with enormous palliative care (PC) needs that begin at the time of diagnosis …

The type and quality of end‐of‐life care varies greatly in ALS; the time to initiate end‐of‐life
care is not defined, and decision making is hampered by logistical and financial barriers …